You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The method can be used with isothermal amplification and paper-based readouts to detect infectious disease drug resistance in low-resource areas.
The DNA synthesis company priced shares of common stock at $28 and increased the expected proceeds from its stock offering to $130 million.
The offering of common stock will be the second for Twist this year and the third since the company made its initial public offering in October 2018.
On a conference call to discuss the firm's fiscal Q1 financial results, Twist executives detailed the firm's vision for near- and long-term growth.
A hearing scheduled for Friday, part of a lawsuit filed by Agilent was cancelled, leading to speculation the sides were close to a settlement.
Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports.
The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.
Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.
In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.